Article
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma.
Cell reports. Medicine - 20 Aug 2024
Nokin Marie-Julie, Darbo Elodie, Richard Elodie, San José Sonia, de Hita Sergio, Prouzet-Mauleon Valérie, Turcq Béatrice, Gerardelli Laura, Crake Rebekah, Velasco Valérie, Koopmansch Benjamin, Lambert Frederic, Xue Jenny Y, Sang Ben, Horne Julie, Ziemons Eric, Villanueva Alberto, Blomme Arnaud, Herfs Michael, Cataldo Didier, Calvayrac Olivier, Porporato Paolo, Nadal Ernest, Lito Piro, Jänne Pasi A, Ricciuti Biagio, Awad Mark M, Ambrogio Chiara, Santamaría David
Abstract excerpt
The current targeted therapy for BRAFV600E-mutant lung cancer consists of a dual blockade of RAF/MEK kinases often combining dabrafenib/trametinib (D/T). This regimen extends survival when compared to single-agent treatments, but disease progression is unavoidable. By using whole-genome CRISPR screening and RNA sequencing, we characterize the vulnerabilities of both persister and D/T-resistant cellular models....
Topics
Join the communities discussing this publication.